Disc Medicine Inc. (IRON) has reported promising additional data from its ongoing Phase 1b study of DISC-0974, targeting patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia. The study includes findings from the 40 mg and 60 mg single ascending dose (SAD) cohorts.
Presented at the 2024 American Society of Nephrology (ASN) Kidney Week in San Diego, CA, the data demonstrated that a single administration of DISC-0974 leads to prolonged suppression of hepcidin, enhances iron mobilization, and boosts erythropoiesis as well as hemoglobin levels in NDD-CKD patients suffering from anemia.
During the SAD segment, participants with Stage 2-5 NDD-CKD received either a single placebo dose (n=7) or DISC-0974 subcutaneously (SC) at varying doses: 28 mg (n=9), 40 mg (n=6), or 60 mg (n=6). The dose escalation process is still ongoing in this stage of the study.
Interim analysis indicated a notable, enduring, and dose-dependent reduction in hepcidin levels from baseline, compared to placebo, across all dosage groups. This reduction exceeded 75% at the highest dose level. Furthermore, there was a significant and prolonged increase in transferrin saturation from baseline over placebo, with the highest dose level showing a median increase up to three times its baseline value. Additionally, an early and continuous rise in mean reticulocyte hemoglobin was observed from baseline in all dose groups, extending through Day 22 and beyond.
